Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn
US private equity firm Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit Mitsubishi Tanabe Pharma in a …
Post
-
-
Impact of proposed US tariffs on pharmaceutical FDI in Canada, Mexico, China and Europe
The pharmaceutical industry is bracing for potentially major disruptions following US President Donald Trump’s announcement of new tariffs on imported …
-
Sanofi increases ownership stake partaking in pharma buyback trend
Just days after taking back some of the stake held by L’Oréal, Sanofi has agreed to repurchase its own shares …
-
Alumis and Acelyrin sign merger agreement
Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction, creating a late-stage clinical …
-
43rd Annual JP Morgan Healthcare Conference 2025 OR
The 43rd Annual JP Morgan Healthcare Conference took place in San Francisco, California on January 13–16, 2025. This annual conference is …
-
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company …
-
How AI is streamlining cell and gene therapy manufacturing
AI has frequently been in the headlines recently due to its potentially transformative capabilities — and the technology is making …
-
Relmada acquires Tourette’s therapy rights from Asarina
Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma. Sepranolone is a neurosteroid being …
-
Treating alcohol addiction: filling the medication gap
With Dry January firmly behind us, many adults are prompted to reassess their relationship with alcohol. Alcohol Change, the UK …
-
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15
Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a daratumumab biosimilar …
-
AstraZeneca’s shares rise as it addresses China investigation
AstraZeneca’s shares rose today (6 February) after the pharma company reported better-than-expected Q4 2024 results. The strong financial performance helped ease …
-
Novo Nordisk plans new study for CagriSema, targets 2026 submission
Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential …
-
FDA grants orphan drug status to Arbor Biotechnologies’ PH1
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation (RPDD) to …
-
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory …
-
Tripartite MoU signed for mRNA production platform in Egypt
EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a memorandum of understanding (MoU) to establish the first …
